History

Introduced by Ciba and marketed in the US as Dianabol from 1958, its development is linked to US team physician Dr. John Ziegler during Cold War Olympic weightlifting competition with the USSR. It was an FDA-approved prescription drug; after the 1962 Kefauver–Harris Amendment and the DESI efficacy review, marketed/approved uses were narrowed to conditions such as post-menopausal osteoporosis and pituitary-deficient dwarfism. Ciba withdrew Dianabol from the US market in 1983 and the FDA withdrew approval of methandrostenolone in 1985; it has no legal US medical use today.

Methandrostenolone — known internationally as metandienone or methandienone, and by the brand name Dianabol — is one of the most famous anabolic-androgenic steroids ever made. It is a synthetic derivative of testosterone, not a peptide, and was the archetypal “oral bulking steroid” of mid-20th-century bodybuilding. Unusually for a performance drug, it was studied in genuine double-blind, placebo-controlled human trials in the 1970s and 1980s, so we can describe its real effects rather than relying on gym lore. This page summarizes that evidence, its legal status, and its substantial safety risks. It contains no doses, cycles, stacks, or protocols.

What it is

Methandrostenolone is a synthetic anabolic-androgenic steroid (AAS) — a modified form of testosterone, chemically 17α-methyl-17β-hydroxyandrost-1,4-dien-3-one (testosterone with an added 17α-methyl group and a 1,2 double bond on the A-ring). The names methandrostenolone, metandienone, methandienone, and Dianabol all refer to the same single molecule.

Like other AAS, it works as an agonist of the androgen receptor (AR). AR binding drives anabolic signaling — increased muscle protein synthesis and nitrogen retention — alongside androgenic effects. It is also a substrate for aromatization to estrogenic metabolites, which contributes to gynecomastia and water retention.

The defining structural feature is 17α-alkylation. The 17α-methyl group slows hepatic first-pass metabolism, which is what makes the drug orally active — and the same feature is what makes 17α-alkylated orals characteristically hepatotoxic (see Safety). This is the key contrast with injectable esterified steroids such as testosterone esters, which are not 17α-alkylated and are not orally hepatotoxic in the same way.

The claims

The non-medical claims for methandrostenolone are straightforward: rapid increases in body weight, lean/muscle mass, and strength, which is why it has historically been promoted as an oral “kickstart” agent in bodybuilding. Historically, the medical claims tracked the approvals of its era — anabolic/weight-restoration uses for osteoporosis and growth deficiency. There is no current legitimate US medical use, and the performance use is both illegal (Schedule III) and banned in sport.

What the evidence actually shows

The strongest human data come from two double-blind, placebo-controlled crossover trials in trained men by Hervey and colleagues:

Hervey et al., Lancet 1976 (PMID 61389): subjects gained body weight, the gain was confined to the lean compartment, muscles increased in size, and there was disproportionate potassium accumulation. Crucially, strength and performance improved over each training period but did not differ significantly between drug and placebo. Plasma cortisol rose and plasma testosterone fell on the drug.
Hervey et al., Clin Sci 1981 (PMID 7018798): body weight, total-body potassium and nitrogen, muscle size, and leg strength/performance all increased significantly on drug but not placebo. The authors cautioned that the proportions of nitrogen and potassium gained were not characteristic of normal muscle, suggesting the measured “anabolism” overstated true contractile-muscle accrual.

Taken together, the best controlled evidence supports real increases in body weight and lean mass / muscle size with the drug plus training. The strength signal was modest and not cleanly separable from training itself in these small trials. Much larger, cleaner causal evidence that supraphysiologic androgens raise muscle size and strength comes from the controlled testosterone literature (Bhasin et al., NEJM 1996, PMID 8637535) — relevant to the AAS class but a different molecule, so it is supportive context rather than direct methandrostenolone data. Older bodybuilding-era reports are largely uncontrolled and anecdotal.

In short: the class effect of anabolic steroids on muscle is firmly established in humans, and methandrostenolone specifically has placebo-controlled data showing lean-mass gains — hence a strong human evidence grade for the headline anabolic effect, with the honest caveat that its independent strength benefit in these trials was smaller and less certain than gym reputation implies.

Legal and regulatory status

Anabolic steroids are Schedule III controlled substances in the US, placed there by the Anabolic Steroids Control Act of 1990 (Pub. L. 101-647), which amended the Controlled Substances Act. The compound is explicitly enumerated in the statutory definition of “anabolic steroid” at 21 U.S.C. § 802(41) under the name “methandienone (17α-methyl-17β-hydroxyandrost-1,4-dien-3-one)” — i.e., methandrostenolone itself.
The list was expanded/redefined by the Anabolic Steroid Control Act of 2004 (Pub. L. 108-358) and again by the Designer Anabolic Steroid Control Act of 2014; the enumerated steroids are codified in DEA regulations at 21 CFR § 1308.13(f).
Practical effect: non-prescription possession, distribution, or import of methandrostenolone is a federal crime, and there is no current FDA approval permitting medical use in the US. Any US supply today is illicit or counterfeit.
Anti-doping (WADA): metandienone is a prohibited anabolic agent under Category S1 (Anabolic Agents), subsection S1.1 (Anabolic Androgenic Steroids), prohibited at all times (in- and out-of-competition). It is one of the most frequently detected AAS in doping controls. The 2026 List clarifies that esters of prohibited anabolic agents are also prohibited.

(Class context: clenbuterol is not FDA-approved for humans and is not a scheduled controlled substance, but is prohibited in sport under WADA S1.2 “Other Anabolic Agents”; human growth hormone is governed by its own distribution statute, 21 U.S.C. § 333(e), rather than the CSA schedules, and falls under WADA S2.)

Safety

Hepatotoxicity (the key concern for 17α-alkylated orals): NIH LiverTox identifies methandienone/methandrostenolone among C-17α-alkylated androgens implicated in four injury patterns: (1) transient serum aminotransferase elevations; (2) an acute, often bland cholestatic syndrome (typically onset within ~1–4 months); (3) peliosis hepatis (blood-filled hepatic sinusoids, with risk of fragile liver and rupture on longer use); and (4) hepatic tumors — adenomas and hepatocellular carcinoma (typically after years of use). The 17α-alkyl group both confers oral activity and underlies this toxicity.
Cardiovascular / lipid: oral AAS, especially 17α-alkylated ones, produce marked adverse lipid changes — large reductions in HDL-C and increases in LDL-C — and are associated with hypertension, left-ventricular hypertrophy/cardiomyopathy, and prothrombotic/atherosclerotic risk with chronic use.
HPTA suppression & fertility: exogenous androgen suppresses the hypothalamic-pituitary-gonadal axis, causing decreased endogenous testosterone, suppressed LH/FSH, testicular atrophy, and impaired spermatogenesis/infertility. Recovery can be prolonged and is not guaranteed.
Estrogenic effects: because metandienone aromatizes, it can cause gynecomastia and fluid retention/edema.
Virilization: in women (and developmentally in adolescents), androgenic effects include deepening of the voice, hirsutism, menstrual disruption, and clitoral enlargement — some of which are irreversible — plus premature growth-plate (epiphyseal) closure in adolescents.
Hematologic: androgens stimulate erythropoiesis and can raise hematocrit/erythrocytosis, increasing thrombotic risk.
Other: acne/oily skin, androgenic alopecia, mood/behavioral changes (irritability, aggression), and psychological dependence have been reported. Illicit supply adds risks of counterfeiting, mislabeling, and contamination.

Bottom line

Methandrostenolone is an oral anabolic-androgenic steroid with a genuine, placebo-controlled evidence base showing it increases body weight and lean mass with training — though its independent effect on strength in those trials was modest. It is not a peptide. In the US it is a Schedule III controlled substance with no legal medical use, it is banned at all times in sport, and it carries serious, well-documented risks to the liver, heart and lipids, hormonal axis, and (irreversibly) to women and adolescents. The anabolic effect is real; so is the harm profile.

Evidence grade: Strong human.

Methandrostenolone (Dianabol)